MANE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veradermics Inc (MANE) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising analyst ratings and a large addressable market, the lack of positive financial performance, absence of recent trading trends, and current negative price momentum suggest holding off on investment until further clarity or improvement in fundamentals.
The stock closed at $56.91 with a pre-market drop of -6.44% and a regular market drop of -3.56%. This indicates a negative short-term price momentum. No trend data is available for further analysis.
Analysts are optimistic about the company's Phase 3 study and the potential for its product VDPHL01 to become the first FDA-approved oral minoxidil for pattern hair loss. The total addressable market is estimated at $30B with significant unmet needs. Analysts have set price targets ranging from $75 to $85, indicating potential upside.
There is no significant insider, hedge fund, or congressional trading activity to indicate confidence in the stock. Additionally, the stock is currently experiencing negative price momentum.
In Q4 2024, the company reported no revenue growth, a net income of -$5.66M, and an EPS of -1.37. Gross margin remains at 0%. There is no indication of financial improvement.
Analysts are highly optimistic, with multiple firms initiating coverage with Buy or Overweight ratings. Price targets range from $75 to $85, and the company is seen as addressing a significant unmet need in a large market.
